A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol

Beatriz Arns, Jaqueline Driemeyer C. Horvath, Gabriela Soares Rech, Guilhermo Prates Sesin, Crepin Aziz Jose Oluwafoumi Agani, Bruna Silveira da Rosa, Tiago Marcon dos Santos, Liliane Spencer Bittencourt Brochier, Alexandre Biasi Cavalcanti, Bruno Martins Tomazini, Adriano Jose Pereira, Viviane Cordeiro Veiga, Giovana Marssola Nascimento, Andre C. Kalil, Alexandre P. Zavascki

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol'. Together they form a unique fingerprint.

Medicine & Life Sciences